1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
2Department of Obstetrics & Gynecology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
3Lois Hole Hospital for Women Menopause Clinic & Grey Nuns Community Hospital Menopause Clinic, Edmonton, Alberta, Canada
4Grey Nuns Community Hospital Menopause Clinic, Edmonton, Alberta, Canada
5Lois Hole Hospital for Women Menopause Clinic, Edmonton, Alberta, Canada
6Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Address correspondence to: Nesé Yuksel, BScPharm, PharmD, FCSHP, NCMP, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, 3-171 Edmonton Clinic Health Academy (ECHA), Edmonton, Alberta, Canada T6G 1C9. E-mail: [email protected]
Received 8 November, 2017
Revised 26 December, 2017
Accepted 26 December, 2017
Funding/support: This research has been funded by generous supporters of the Lois Hole Hospital for Women through the Women and Children's Health Research Institute (WCHRI).
Financial disclosure/conflicts of interest: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (forms available upon request) and declare no support from any organization for the submitted work, and no financial relationships with any organizations that might have an interest in the submitted work in the previous three years. NY has provided continuing education and/or participated in Advisory Boards/Consult Meetings for Pfizer Canada and Aspen Pharmaceuticals. TS has provided continuing education and/or participated in Advisory Boards/Consult Meetings for Pfizer Canada.
Ethical approval: The study was approved by the University of Alberta Human Research Ethics Board (ID#: Pro00054435).
